Psychotic Disorders Clinical Trial
Official title:
Is Health Coaching a Useful Clinical Tool to Facilitate Healthy Lifestyle Change and Improve Metabolic Health in People With Psychotic Illness?
Verified date | November 2015 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
Antipsychotic medications frequently cause metabolic side-effects, such as abdominal
obesity, high blood pressure, cholesterol abnormalities, and blood sugar dysregulation, all
of which can lead to what is known as the Metabolic Syndrome and serious long-term
cardiovascular health problems. Therefore, it is important that metabolic issues be
addressed as part of a holistic approach to the mental health treatment of these patients.
As with the general population, improving metabolic health involves lifestyle changes -
i.e., addressing daily habits regarding eating, physical exercise, stress and sleep
management, and lifestyle habits such as smoking. However, there is growing recognition in
the medical field that education is not enough for people to create meaningful and sustained
lifestyle change. The emerging field of Integrative Health Coaching addresses this issue and
provides a clinical framework for helping people successfully develop and achieve
personalized lifestyle goals. The investigators have therefore decided to investigate
whether health coaching techniques may have benefit in addressing metabolic health issues in
people with psychosis disorders. The intent is to complement usual psychiatric and medical
care, and also promote patient engagement in managing one's overall health.
This study will investigate whether Integrative Health Coaching is a useful clinical tool to
facilitate healthy lifestyle behaviour and thereby improve metabolic health in people with
psychosis disorders.
Status | Enrolling by invitation |
Enrollment | 40 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Subjects must have a primary working diagnosis of schizophrenia/schizoaffective disorder, or bipolar disorder, or psychosis not otherwise specified (PNOS) - Subjects must be prescribed an atypical (or 'second-generation') antipsychotic drug Exclusion Criteria: |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Canada | Vancouver/Richmond Early Psychosis Intervention Clinic | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | Vancouver Coastal Health Research Institute |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Scores on the Short-Form 36 | Scores on the Short-Form 36 (a standardized, validated questionnaire measuring general health) will be compared between patients in the Health Coaching group versus patients receiving only standard care. | Baseline, month 1, month 2, month 3, and month 6 | No |
Primary | Scores on The Three Factor Eating Questionnaire (TFEQ) | Scores on the Three Factor Eating Questionnaire (a questionnaire measuring cognitive restraint of eating, disinhibition, and hunger) will be compared between patients in the Health Coaching group, versus patients receiving only standard care. | Baseline, month 1, month 2, month 3, and month 6 | No |
Primary | Scores on The Health Value Scale | Scores on the Health Value Scale (a questionnaire measuring value placed on health) will be compared between patients in the Health Coaching group, versus patients receiving standard care only. | Baseline, month 1, month 2, month 3, and month 6 | No |
Secondary | Waist circumference | Change in waist circumference over 6 months, and comparison of the change in waist circumference between patients in the Health Coaching group, versus patients receiving standard care only. | Baseline, month 1, month 2, month 3, and month 6 | No |
Secondary | Blood Pressure | Change in systolic and diastolic blood pressure over 6 months, and comparison of the change in systolic and diastolic blood pressure between patients receiving Health Coaching, and patients receiving standard care only. | Baseline, month 1, month 2, month 3, and month 6 | No |
Secondary | Heart Rate | Change in heart rate over 6 months, and comparison of the change in heart rate between patients receiving Health Coaching, versus patients receiving standard care only. | Baseline, month 1, month 2, month 3, and month 6 | No |
Secondary | Fasting plasma glucose | Change in fasting plasma glucose over 6 months, and comparison of the change in fasting plasma glucose between patients in the Health Coaching group, versus patients receiving standard care only. | Baseline, month 1, month 2, month 3, and month 6 | No |
Secondary | Fasting total cholesterol | Change in fasting total cholesterol over 6 months, and comparison of the change in fasting total cholesterol between patients in the Health Coaching group, versus patients receiving standard care only. | Baseline, month 1, month 2, month 3, and month 6 | No |
Secondary | Fasting cholesterol subfractions | Change in fasting cholesterol subfractions (LDL-C, HDL-C) over 6 months, and comparison of the change in fasting cholesterol subfractions between patients receiving Health Coaching, versus patients receiving standard care only. | Baseline, month 1, month 2, month 3, and month 6 | No |
Secondary | Fasting triglycerides | Change in fasting triglycerides over 6 months, and comparison of the change in fasting triglycerides between patients receiving Health Coaching, versus patients receiving standard care only. | Baseline, month 1, month 2, month 3, and month 6 | No |
Secondary | Fasting insulin | Change in fasting insulin over 6 months, and comparison of the change in fasting insulin between patients receiving Health Coaching, versus patients receiving standard care only. | Baseline, month 1, month 2, month 3, and month 6 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00253240 -
Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population
|